Gloucester Pharmaceuticals, Inc. Release: ISTODAX(R) Incorporated Into National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology(TM) for the Treatment of Cutaneous T-cell Lymphoma (CTCL)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL). ISTODAX, a member of a new class of cancer drugs known as histone deacetylase (HDAC) inhibitors, received FDA approval in early November for the treatment of CTCL in patients who have received at least one prior systemic therapy.